Insulin Degludec
10 Topics Found
Drug Index
Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba.[2] It is administered via subcutaneous injection once daily to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making it a once-daily basal insulin,&...
Drug Index
Insulin degludec/liraglutide, sold under the brand name Xultophy, is a fixed-dose combination medication for the treatment of adults with type 2 diabetes to improve glycemic control in combination with diet and exercise.[4][5] It contains insulin degludec and liraglutide.[4][5] It is administered by subcutaneous injection.[4][5] The most common side effects include hypoglycaemia (low blood glucose)...
Drug Index
Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba.[2] It is administered via subcutaneous injection once daily to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making it a once-daily basal insulin,&...
Insulin Degludec
Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba.[2] It is administered via subcutaneous injection once daily to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making it a once-daily basal insulin,&...
Insulin Degludec + Liraglutide
Insulin degludec/liraglutide, sold under the brand name Xultophy, is a fixed-dose combination medication for the treatment of adults with type 2 diabetes to improve glycemic control in combination with diet and exercise.[4][5] It contains insulin degludec and liraglutide.[4][5] It is administered by subcutaneous injection.[4][5] The most common side effects include hypoglycaemia (low blood glucose)...
Insulin Degludec + Insulin Aspart
Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba.[2] It is administered via subcutaneous injection once daily to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making it a once-daily basal insulin,&...
NDC Database
Tresiba 200 U/Ml Subcutaneous Injection, Solution by A-s Medication Solutions ## Package Codes: 50090-3491-0 ## Active Ingredients: Insulin Degludec
NDC Database
Tresiba 200 U/Ml Subcutaneous Injection, Solution by Novo Nordisk ## Package Codes: 0169-2550-13, 0169-2550-97 ## Active Ingredients: Insulin Degludec
NDC Database
Tresiba 100 U/Ml Subcutaneous Injection, Solution by Novo Nordisk ## Package Codes: 0169-2660-15, 0169-2660-97 ## Active Ingredients: Insulin Degludec
NDC Database
Tresiba 100 U/Ml Subcutaneous Injection, Solution by Novo Nordisk ## Package Codes: 0169-2662-11, 0169-2662-90 ## Active Ingredients: Insulin Degludec